AstraZeneca Expects 2024 Total Revenue And Core EPS To Increase By A Low Double-Digit To Low Teens Percentage At CER
Portfolio Pulse from Benzinga Newsdesk
AstraZeneca projects a low double-digit to low teens percentage increase in Total Revenue and Core EPS for FY 2024 at CER. Collaboration Revenue is expected to rise significantly, while other operating income will see a substantial decrease due to the absence of previous gains. The Core Tax rate is anticipated to be between 18-22%.
February 08, 2024 | 7:31 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AstraZeneca expects significant growth in Total Revenue and Core EPS for FY 2024, with a substantial increase in Collaboration Revenue but a decrease in other operating income.
The positive guidance for FY 2024, including expected growth in Total Revenue and Core EPS, indicates a strong financial outlook for AstraZeneca. The substantial increase in Collaboration Revenue suggests successful partnerships and transactions, which could drive investor optimism. However, the decrease in other operating income, due to the absence of previous gains, might slightly temper the overall positive impact.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100